European Association of Nuclear Medicine Focus 5 : Consensus on Molecular Imaging and Theranostics in Prostate Cancer

Oprea-Lager, Daniela-ElenaMacLennan, StevenBjartell, AndersBriganti, AlbertoBurger, Irene Ade Jong, IgleDe Santis, MariaEberlein, UtaEmmett, LouiseFizazi, KarimGillessen, SilkeHerrmann, KenHeskamp, SandraIagaru, AndreiJereczek-Fossa, Barbara AlicjaKunikowska, JolantaLam, MarnixNanni, CristinaO'Sullivan, Joe MPanebianco, ValeriaSala, EvisSathekge, MikeSosnowski, RomanTilki, DeryaTombal, BertrandTreglia, GiorgioTunariu, NinaWalz, JochenYakar, DeryaDierckx, RudiSartor, OliverFanti, Stefano2024-03-202024-03-202024-01Oprea-Lager, D-E, MacLennan, S, Bjartell, A, Briganti, A, Burger, I A, de Jong, I, De Santis, M, Eberlein, U, Emmett, L, Fizazi, K, Gillessen, S, Herrmann, K, Heskamp, S, Iagaru, A, Jereczek-Fossa, B A, Kunikowska, J, Lam, M, Nanni, C, O'Sullivan, J M, Panebianco, V, Sala, E, Sathekge, M, Sosnowski, R, Tilki, D, Tombal, B, Treglia, G, Tunariu, N, Walz, J, Yakar, D, Dierckx, R, Sartor, O & Fanti, S 2024, 'European Association of Nuclear Medicine Focus 5 : Consensus on Molecular Imaging and Theranostics in Prostate Cancer', European Urology, vol. 85, no. 1, pp. 49-60. https://doi.org/10.1016/j.eururo.2023.09.0030302-2838ORCID: /0000-0002-2691-8421/work/148506167https://hdl.handle.net/2164/23082Funding/Support and role of the sponsor: This research was funded by the EANM and supported by unrestricted grants from Advanced Accelerator Applications—a Novartis company, Monrol, Spectrum Dynamics Medical Ltd., Blue Earth Diagnostics, GE HealthCare, ITM Isotope Technologies Munich SE, Siemens Healthineers, and Telix Pharmaceuticals. These sponsors had no direct or indirect influence on the programme and content of the EANM Focus 5 meeting and the writing or content of this consensus statement. Acknowledgements: We would like to thank Evelyn Mansutti, Susanne Koebe, Andrea Csismazia, Jutta Peter, Petra Neubauer, Andreas Felser, and Henrik Silber (all from EANM) for project management. We also acknowledge all who participated in EANM Focus 5 meeting and especially the patients who participated in clinical and research projects, making it possible to inform expert opinion.12861676engSDG 3 - Good Health and Well-beingProstate CancerTheranosticsNuclear MedicineSystemic radioligand therapyMolecular hybrid imagingRC0254 Neoplasms. Tumors. Oncology (including Cancer)Supplementary DataRC0254European Association of Nuclear Medicine Focus 5 : Consensus on Molecular Imaging and Theranostics in Prostate CancerJournal article10.1016/j.eururo.2023.09.003851